Diamyd Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Diamyd Medical hat ein Gesamteigenkapital von SEK181.2M und eine Gesamtverschuldung von SEK0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen SEK226.5M bzw. SEK45.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

SEK 0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	SEK 162.38m
Eigenkapital	SEK 195.45m
Gesamtverbindlichkeiten	SEK 52.75m
Gesamtvermögen	SEK 248.20m

Jüngste Berichte zur Finanzlage

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

Feb 02

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Sep 22

Recent updates

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

Feb 02

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Sep 22

What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition

Jan 22

Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative

Nov 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: DMYD BDie kurzfristigen Aktiva des Unternehmens (SEK159.8M) übersteigen seine kurzfristigen Passiva (SEK20.5M).

Langfristige Verbindlichkeiten: DMYD BDie kurzfristigen Vermögenswerte des Unternehmens (SEK159.8M) übersteigen seine langfristigen Verbindlichkeiten (SEK24.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: DMYD B ist schuldenfrei.

Schulden abbauen: DMYD B hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: DMYD B auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: DMYD B verfügt über eine ausreichende Liquiditätsreserve für 1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 29.7% pro Jahr abnimmt.

Diamyd Medical Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Recent updates

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold kr651k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New minor risk - Share price stability

We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Chairman recently bought kr72k worth of stock

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Diamyd Medical AB (Publ) Announces Changes of the Board

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Price target decreased by 27% to kr19.00

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

CEO & President recently bought kr88k worth of stock

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Price target increased to kr19.50

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Price target increased to kr19.50

Director recently sold kr1.0m worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings: Revenues miss analyst expectations

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold kr3.7m worth of stock

Diamyd Medical Pauses Start of Phase III Trial

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

CEO & President recently bought kr112k worth of stock

CEO & President recently bought kr112k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months

Investor sentiment improved over the past week

the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July

Director recently sold kr267k worth of stock

Second quarter 2021 earnings released

Diamyd Medical AB (publ) Announces Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

New 90-day low: kr25.25

Director recently sold kr1.2m worth of stock

New 90-day low: kr26.00